Health

Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree

Recognized for pioneering work in integrin receptor biology, leading to new treatments for multiple autoimmune disorders

Founder and Director Scientific advisory board Member of Morphic Therapeutic

Waltham, Mass.And the September 28, 2022 (GLOBE NEWSWIRE) – Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies to treat serious chronic diseases, today pays tribute to Timothy Springer, Ph.D. for receiving his 2022 Albert Lasker Basic Medical Research prize. Dr. Springer He was honored for the discovery of integrin receptors, key mediators of cellular interactions in physiology and disease.

Read:Alphabet’s Venture Arm GV Eyes Brick-and-Mortar SMI Investments

The Lasker Awards honor the contributions of leaders who have made significant advances in the understanding, diagnosis, treatment, treatment, and prevention of human disease, and have been widely recognized as America’s most recognized biomedical research award.

Tim Springer He received the Lasker Prize for discovering integrins, a class of transmembrane proteins that allow immune system molecules to adhere to their targets. Dr. Springer He shares the award with Dr. Richard O. Heinz friendship. Erkki Ruoslahti who made separate discoveries when combined with Dr. Springer, led to the understanding of the entire family of integrin receptors. The discovery and understanding of the function of integrin triggered research and development efforts resulting in new treatment methods for a variety of autoimmune disorders, neurodegenerative diseases, as well as thrombotic conditions and eye diseases.

Read:Disposable Medical Gloves Market Size to Surpass US$ 15.09

“The 2022 Lasker Prize is a fitting recognition of Tim Springer’s tremendous contributions to science and medicine. Tim’s work has led to many new treatments for patients suffering from devastating conditions around the world, and our warmest congratulations,” Pravin TiberniniCEO of morphic. “I also thank Tim because without his research into the integrin space, morphic It simply won’t exist. Beyond the discovery of the class of integrin, Tim continues to advance a deeper understanding of the importance of receptor motifs through advanced crystallization methods. Tim has remained a consistent scientific advisor and strategic advisor to our company, and I look forward to collaborating with him for years to come.”

Around Timothy A. SpringerPh.DDr. Springer He is an immunologist and biophysicist who serves as a professor for the Latham family in Harvard Medical School and Boston Children’s Hospital. Dr. Springer Integrins and their ligands were discovered in the 1980s, and since then, have worked to elucidate the regulation of their biological function. His pioneering work resulted in the detailed characterization of the integrin structure and a solid understanding of the biophysical phenomena underlying its activation. This has led to the founding of several biotech companies (LeukoSite, Scholar Rock, and Morphic Therapeutic) and approved therapies including Amevive.®Raptiva®Campath®philcad®and Entyvio®. Timothy A. Springer He received his Bachelor’s degree in Biochemistry from University of California In 1971, he received his Ph.D. He received his Ph.D. in Molecular Biology and Biochemistry from Harvard University in 1976, and was awarded a fellowship Cesar Milstein in Cambridge, England.

Read:How good are almonds for gut health?

About morphology
Morphic Therapeutic is a biopharmaceutical company that develops a range of oral integrin therapies to treat serious chronic diseases, including autoimmune, cardiovascular, metabolic, fibrosis, and cancer diseases. morphic It is also developing its pipeline and exploration activities in collaboration with Janssen and Schrödinger using its MInT technology platform that advances the company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Cautionary note regarding forward-looking statements
This press release contains “forward-looking” statements within the meaning of the Securities Act of 1933, as amended, the Securities Act of 1934 and its amendments, and the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to Limitations: The ability of the MInT platform to discover candidate drugs, Morphic’s plans for the development and commercialization of oral and small molecule integrin therapies and any proposed timing, initiation, implementation and completion of a Phase II MORF-057 clinical trial, any expectations regarding safety, efficacy, timing, and ability to start or complete studies and/or clinical trials and regulatory approvals for MORF-057 and other candidates under development, timing of further data submission and the ability of MORF-057 to treat inflammatory bowel disease, including ulcerative colitis, or related indications. Statements that include words such as “believe,” “plan,” “continue,” “expect,” “will,” “develop,” “indicate,” “potential,” “expect” or “continued” and statements in the future tense are forward-looking statements. . These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if not fully realized or proven incorrect, could cause our results to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause Morphic’s actual activities or results to differ materially from those expressed in any forward-looking statement, including the risks and uncertainties in this press release and other risks set forth in our files with Securities and Exchange Commission, including Morphic’s or a partner’s ability to complete a current or future clinical trial of any of our current or future product candidates, or to develop or obtain regulatory approval for or market any candidate product, Morphic’s ability to protect intellectual property, and the potential impact of COVID-19 pandemic, and sufficient cash and cash equivalents and our investments to fund our operations. These forward-looking statements speak only as of the date hereof morphic It specifically disclaims any obligation to update these forward-looking statements or reasons for different actual results, whether as a result of new information, future events or otherwise, except as required by law.

Contacts
Lasker Media FoundationEric M. Gewertz[email protected]
+ 1-212-843-8290

morphological therapyKatie Vincent[email protected]

basic logo

Source: Morphic Therapeutic

2022 GlobeNewswire, Inc. , Source press releases

Previous post
Don’t make NHS and public services pay the bill fortax cuts, Kwarteng told
Next post
‘Almost don’t want to’ – Liverpool captain Jordan Henderson makes Jude Bellingham future admission